Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation

Activating KRAS mutations are present in 25% of human cancer. Although oncogenic Ras was deemed “undruggable” in the past, recent efforts led to the development of pharmacological inhibitors targeting the KRAS(G12C) mutant, which have shown promise in early clinical trials. The development of allele...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Delong, Yang, Shengyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491749/
https://www.ncbi.nlm.nih.gov/pubmed/32939510
http://dx.doi.org/10.1016/j.xinn.2020.100035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491749/
https://www.ncbi.nlm.nih.gov/pubmed/32939510
http://dx.doi.org/10.1016/j.xinn.2020.100035

Ejemplares similares